Literature DB >> 499308

Pharmacokinetics of cefoxitin in patients with normal or impaired renal function.

M J Garcia, A Dominguez-Gil, J M Tabernero, J A Sanchez Tomero.   

Abstract

The pharmacokinetics of cefoxitin have been determined after a single i.v. injection of 15 mg/kg body weight in 10 patients with normal renal function and 20 patients with varying degrees of renal impairment. The kinetics of the antibiotic followed an open two-compartment model. In patients with normal renal function the following pharmacokinetic parameters were found: alpha = 8.66 h-1 beta = 1.21 h-1 K12 = 3.47 h-1 K21 = 3.17 h-1 K13 = 3.15 h-1 Vc = 4.24 l. Vp = 4.87 l. Vdss = 9.11 l. In the patients with renal impairment there was a significant decrease in alpha, beta, K12, K21 and K13, and an increase in the apparent volume of distribution. The degree of plasma protein binding in patients with normal renal function was 73.6% and this was diminished in patients with renal impairment. A linear relationship between K13 of cefoxitin and creatinine clearance was demonstrated. The dosage regimen for patients with renal impairment should be adjusted by modifying the dosage interval whilst maintaining the amount administered.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 499308     DOI: 10.1007/bf00563118

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  3 in total

1.  Cefoxitin: a hospital study.

Authors:  A M Geddes; L P Schnurr; A P Ball; D McGhie; G R Brookes; R Wise; J Andrews
Journal:  Br Med J       Date:  1977-04-30

2.  Cefoxitin, a semisynthetic cephamycin antibiotic: in vivo evaluation.

Authors:  A K Miller; E Celozzi; Y Kong; B A Pelak; D Hendlin; E O Stapley
Journal:  Antimicrob Agents Chemother       Date:  1974-01       Impact factor: 5.191

3.  Cefoxitin, a new semi-synthetic cephamycin: an in-vitro and in-vivo comparison with cephalothin.

Authors:  J Kosmidis; J M Hamilton-Miller; J N Gilchrist; D W Kerry; W Brumfitt
Journal:  Br Med J       Date:  1973-12-15
  3 in total
  10 in total

Review 1.  Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).

Authors:  R Zini; P Riant; J Barré; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

2.  Pharmacokinetics of cefmetazole administered intramuscularly and intravenously to healthy adults.

Authors:  J Rodriguez-Barbero; E L Mariño; A Dominguez-Gil
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

Review 3.  Drug therapy in patients undergoing peritoneal dialysis. Clinical pharmacokinetic considerations.

Authors:  T W Paton; W R Cornish; M A Manuel; B G Hardy
Journal:  Clin Pharmacokinet       Date:  1985 Sep-Oct       Impact factor: 6.447

4.  Alteration of drug-protein binding in renal disease.

Authors:  M M Reidenberg; D E Drayer
Journal:  Clin Pharmacokinet       Date:  1984-01       Impact factor: 6.447

5.  The influence of uremia on the accessibility of phosphomycin into interstitial tissue fluid.

Authors:  C Fernandez Lastra; E L Mariño; A Dominguez-Gil; J M Tabernero; A Gonzalez Lopez; M Yuste Chaves
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

6.  Pharmacokinetic effects of altered plasma protein binding of drugs in renal disease.

Authors:  F Keller; M Maiga; H H Neumayer; H Lode; A Distler
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1984 Jul-Sep       Impact factor: 2.441

7.  Pharmacokinetics of cefoxitin administered by i.v. infusion to patients with a pleural effusion.

Authors:  M J Otero; M J Garcia; M Barrueco; A Dominguez-Gil; F Gomez; J Portugal Alvarez
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

Review 8.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

9.  An Overview of the Protein Binding of Cephalosporins in Human Body Fluids: A Systematic Review.

Authors:  C Jongmans; A E Muller; P Van Den Broek; B De Melo Cruz De Almeida; C Van Den Berg; J Van Oldenrijk; P K Bos; B C P Koch
Journal:  Front Pharmacol       Date:  2022-06-28       Impact factor: 5.988

10.  Disposition of cefoxitin in patients with ascites.

Authors:  M J Garcia; A Dominguez-Gil; F D Perez; F P Rodriguez; F D Moronta
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.